Adam J. Dupuy

University of Iowa — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

39h-index6.2kcitations238works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(41), CRISPR and Genetic Engineering(39), Glioma Diagnosis and Treatment(29), Melanoma and MAPK Pathways(24), Animal Genetics and Reproduction(23)

Publications236 total

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines
Gynecologic Oncology·2025
Auranofin Synergistically Sensitizes KEAP1 Mutant and WT NSCLCs to P-AscH--induced Cell Killing by a Thiol and H2O2 Dependent Mechanism
Free Radical Biology and Medicine·2025
A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition
Oncogene·2025Open Access
Integrated genomic approaches to characterize biologic responses to MEK inhibition and mechanisms of therapeutic resistance in low-grade serous ovarian cancer
Gynecologic Oncology·2025
A forward genetic screen identifies potassium channel essentiality in SHH medulloblastoma maintenance
Developmental Cell·2025· 2 cited
A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition
2024· 1 citedOpen Access
Single allele loss-of-function mutations select and sculpt conditional cooperative networks in breast cancer
UNC Libraries·2024Open Access
Abstract 1998: ABCB1 promotes uveal melanoma cell resistance to FR900359 and identifies a tumor cell subpopulation with a distinct gene expression signature
Cancer Research·2024
Abstract A026: Identifying mechanisms to target in combination with trametinib to improve therapeutic efficacy in low-grade serous ovarian cancer
Cancer Research·2024
Single-cell genomics analysis reveals complex genetic interactions in an <i>in vivo</i> model of acquired BRAF inhibitor resistance
NAR Cancer·2024· 2 citedOpen Access
Characterization of genetic mechanisms of ovarian tumor progression using sleeping beauty mutagenesis in vivo (2296)
Gynecologic Oncology·2023Open Access
Identifying mechanisms of therapeutic resistance in low-grade serous ovarian cancer (2282)
Gynecologic Oncology·2023Open Access
Understanding cancer drug resistance with Sleeping Beauty functional genomic screens: Application to MAPK inhibition in cutaneous melanoma
iScience·2023· 5 citedOpen Access
Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancer
Nature Communications·2023· 9 citedOpen Access
Supplementary Table 3 from A Genetic Screen to Identify Gain- and Loss-of-Function Modifications that Enhance T-cell Infiltration into Tumors
2023Open Access
Supplementary Table 2 from A Genetic Screen to Identify Gain- and Loss-of-Function Modifications that Enhance T-cell Infiltration into Tumors
2023Open Access
Supplementary Table 3 from A Genetic Screen to Identify Gain- and Loss-of-Function Modifications that Enhance T-cell Infiltration into Tumors
2023Open Access
Source Data from A Genetic Screen to Identify Gain- and Loss-of-Function Modifications that Enhance T-cell Infiltration into Tumors
2023Open Access
Source Data from A Genetic Screen to Identify Gain- and Loss-of-Function Modifications that Enhance T-cell Infiltration into Tumors
2023Open Access
Supplementary Table 1 from A Genetic Screen to Identify Gain- and Loss-of-Function Modifications that Enhance T-cell Infiltration into Tumors
2023Open Access
page 1 of 12Next →

Frequent Co-authors

David A. Largaespada(20), Nancy A. Jenkins(14), Neal G. Copeland(13), Jesse D. Riordan(11), Todd E. Scheetz(8), Aaron L. Sarver(7), Lara S. Collier(5), Timothy K. Starr(5), Benjamin T. Brett(5), Vincent W. Keng(5), Laura M. Rogers(5), Keiko Akagi(4), Alistair G. Rust(4), David J. Adams(4), Kishore Nannapaneni(4), Barbara R. Tschida(4), William A. Weiss(3), Corey M. Carlson(3), Kevin A.T. Silverstein(3), Ilze Matise(3)